Coban, Cevayir
2020-08-31T15:54:55Z
2020-08-31T15:54:55Z
2020
0952-7915
https://doi.org/10.1016/j.coi.2020.07.005
http://hdl.handle.net/20.500.12010/12462
Due to the rapid onset and spread of the COVID-19 pandemic,
the treatment of COVID-19 patients by hydroxychloroquine
alone or in combination with other drugs has captured a great
deal of attention and triggered considerable debate.
Historically, the worldwide use of quinoline based-drugs has
led to a spectacular reduction in death from malaria.
Unfortunately, scientists have been forced to seek alternative
drugs to treat malaria due to the emergence of chloroquineresistant parasites in the 1960s. The repurposing of
hydroxychloroquine against viral infections, various types of
cancer and autoimmune diseases has been ongoing for more
than 70 years, with no clear understanding of its mechanism of
action (MOA). Here, we closely examine the MOA of this old but
influential drug in and beyond malaria. Better insights into how
chloroquine targets the host’s cellular and immune responses
may help to develop applications against to new pathogens
and diseases, and perhaps even restore the clinical utility of
chloroquine against malaria.
10 páginas
image/jepg
eng
Current opinion in inmunology
reponame:Expeditio Repositorio Institucional UJTL
instname:Universidad de Bogotá Jorge Tadeo Lozano
Chloroquine
Malaria
The host targeting effect of chloroquine in malaria
Artículo
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
info:eu-repo/semantics/embargoedAccess
info:eu-repo/semantics/acceptedVersion
Acceso restringido
https://doi.org/10.1016/j.coi.2020.07.005
http://purl.org/coar/resource_type/c_2df8fbb1